公开(公告)号：US20090176780A1

公开(公告)日：2009-07-09

申请号：US11959341

申请日：2007-12-18

Applicant: Anjali Pandey ,  Robert M. Scarborough ,  Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shinichi Ide ,  Eiji Tsukuda ,  Nee Junko Irie Junko Sasaki ,  Shoji Oda

Inventor： Anjali Pandey ,  Robert M. Scarborough ,  Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shinichi Ide ,  Eiji Tsukuda ,  Nee Junko Irie Junko Sasaki ,  Shoji Oda

IPC: A61K31/5377 ,  A61K31/517

CPC classification number: C07D401/12 ,  C07D239/94 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12

Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.

Abstract translation: 本发明涉及对抑制这种激酶活性的激酶磷酸化具有抑制活性的含氮杂环化合物及其药学上可接受的盐。 本发明还涉及通过抑制激酶的磷酸化来抑制哺乳动物的激酶和治疗疾病状态的方法。 在一个特定方面，本发明提供了抑制PDGF受体的磷酸化以阻止异常细胞生长和细胞游动的含氮杂环化合物及其药学上可接受的盐，以及预防或治疗细胞增殖性疾病如动脉硬化，血管 重建，癌症和肾小球硬化症。

公开(公告)号：US06750218B2

公开(公告)日：2004-06-15

申请号：US10227302

申请日：2002-08-26

Applicant: Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shigeki Fujiwara ,  Shinichi Ide ,  Eiji Tsukuda ,  Junko Irie ,  Shoji Oda

Inventor： Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shigeki Fujiwara ,  Shinichi Ide ,  Eiji Tsukuda ,  Junko Irie ,  Shoji Oda

IPC: C07D48704

CPC classification number: C07D401/12 ,  A61K31/496 ,  A61K31/502 ,  A61K31/517 ,  C07D215/46 ,  C07D217/22 ,  C07D237/34 ,  C07D239/94 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D487/04

Abstract: 1,3 Diazines according to formula: and pharmaceutically acceptable salts thereof inhibit phosphorylation of platelet-derived growth factor receptor and thereby hinder abnormal cell growth and cell wandering.

Abstract translation: 1,3根据式的二嗪类及其药学上可接受的盐抑制血小板衍生生长因子受体的磷酸化，从而阻碍异常细胞生长和细胞游动。

公开(公告)号：US06207667B1

公开(公告)日：2001-03-27

申请号：US09481544

申请日：2000-01-12

Applicant: Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shigeki Fujiwara ,  Shinichi Ide ,  Eiji Tsukuda ,  Junko Irie ,  Shoji Oda

Inventor： Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shigeki Fujiwara ,  Shinichi Ide ,  Eiji Tsukuda ,  Junko Irie ,  Shoji Oda

IPC: A61K31535

CPC classification number: C07D401/12 ,  A61K31/496 ,  A61K31/502 ,  A61K31/517 ,  C07D215/46 ,  C07D217/22 ,  C07D237/34 ,  C07D239/94 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D487/04

Abstract: 1,3 Diazines according to formula (I): and pharmaceutically acceptable salts thereof inhibit phosphorylation of platelet-derived growth factor receptor and thereby hinder abnormal cell growth and cell wandering. The compounds may be used to treat or prevent cell-proliferative disorders such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.

Abstract translation: 1,3根据式（I）的二嗪类及其药学上可接受的盐抑制血小板衍生生长因子受体的磷酸化，从而阻碍异常细胞生长和细胞游动。 该化合物可用于治疗或预防细胞增殖性疾病如动脉硬化，血管重构，癌症和肾小球硬化。

公开(公告)号：US06169088A

公开(公告)日：2001-01-02

申请号：US09088199

申请日：1998-06-01

Applicant: Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shigeki Fujiwara ,  Shinichi Ide ,  Eiji Tsukuda ,  Junko Irie ,  Shoji Oda

Inventor： Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shigeki Fujiwara ,  Shinichi Ide ,  Eiji Tsukuda ,  Junko Irie ,  Shoji Oda

IPC: A61K31495

CPC classification number: C07D401/12 ,  A61K31/496 ,  A61K31/502 ,  A61K31/517 ,  C07D215/46 ,  C07D217/22 ,  C07D237/34 ,  C07D239/94 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D487/04

Abstract: 1,3 Diazines and pharmaceutically acceptable salts thereof inhibit phosphorylation of platelet-derived growth factor receptor and thereby hinder abnormal cell growth and cell wandering. The compounds may be used to treat or prevent cell-proliferative disorders such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.

Abstract translation: 1,3二嗪及其药学上可接受的盐抑制血小板衍生生长因子受体的磷酸化，从而阻碍异常细胞生长和细胞游动。 该化合物可用于治疗或预防细胞增殖性疾病如动脉硬化，血管重构，癌症和肾小球硬化。

公开(公告)号：US06472391B2

公开(公告)日：2002-10-29

申请号：US09734918

申请日：2000-12-13

Applicant: Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shigeki Fujiwara ,  Shinichi Ide ,  Eiji Tsukuda ,  Junko Irie ,  Shoji Oda

Inventor： Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shigeki Fujiwara ,  Shinichi Ide ,  Eiji Tsukuda ,  Junko Irie ,  Shoji Oda

IPC: A61K3153

CPC classification number: C07D401/12 ,  A61K31/496 ,  A61K31/502 ,  A61K31/517 ,  C07D215/46 ,  C07D217/22 ,  C07D237/34 ,  C07D239/94 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D487/04

Abstract: 1,2,3 Triazines according to formula (I): and pharmaceutically acceptable salts thereof inhibit phosphorylation of platelet-derived growth factor receptor and thereby hinder abnormal cell growth and cell wandering.

Abstract translation: 根据式（I）的1,2,3-三嗪及其药学上可接受的盐抑制血小板衍生生长因子受体的磷酸化，从而阻碍异常细胞生长和细胞游动。